5167-14-6 Usage
General Description
Hypoxanthine-1-oxide is a chemical compound that is an intermediate in the metabolism of purine nucleotides. It is formed naturally in the body as a result of purine breakdown and can also be found in certain foods. Hypoxanthine-1-oxide has been studied for its potential role in inflammatory processes and oxidative stress in the body. In addition, it has been investigated for its potential as a therapeutic target in the treatment of diseases such as gout and cancer. Further research is needed to fully understand the biological roles and potential applications of hypoxanthine-1-oxide.
Check Digit Verification of cas no
The CAS Registry Mumber 5167-14-6 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 5,1,6 and 7 respectively; the second part has 2 digits, 1 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 5167-14:
(6*5)+(5*1)+(4*6)+(3*7)+(2*1)+(1*4)=86
86 % 10 = 6
So 5167-14-6 is a valid CAS Registry Number.
InChI:InChI=1/C5H5N4O2/c10-5-3-4(7-1-6-3)8-2-9(5)11/h1-3,5,10H/q+1
5167-14-6Relevant articles and documents
Synthesis and biological activities of C-2, N-9 substituted 6- benzylaminopurine derivatives as cyclin-dependent kinase inhibitor
Oh, Chang-Hyun,Lee, Su-Chul,Lee, Ki-Soo,Woo, Eun-Rhan,Hong, Chang Yong,Yang, Boem-Seok,Baek, Dae Jin,Cho, Jung-Hyuck
, p. 187 - 190 (1999)
In this study, C-2, N-9 substituted 6-benzylaminopurine derivatives were synthesized and their inhibitory effects on cyclin-dependent kinase (CDK2) were evaluated. The effect of substituents at the C-2 and N-9 positions of substituted purine was investigated. Among the compounds tested, compound 7b- iii (6-benzylamino-2-thiomorpholinyl-9-isopropylpurine) was the most active inhibitor (IC50 = 0.9 μM). Compound 7b-iii showed 10-fold higher activity compared to olomoucine and almost the same activity as roscovitine. Results from structure-activity relationship studies should allow the design of more potent and selective CDK inhibitors, which may provide an effective therapy for cancer or other CDK dependent diseases.
